2 weeks Ago By Defense World Staff
Geode Capital Management LLC increased its holdings in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 1.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
The institutional investor owned 3,482,136 shares of the biopharmaceutical company’s stock after purchasing an additional 33,536 shares during the quarter. Geode Capital Management LLC owned approximately 1.84% of Arbutus Biopharma worth $11,390,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. SBI Securities Co. Ltd.
purchased a new position in shares of Arbutus Biopharma during the fourth quarter valued at about $236,000. Vanguard Group Inc. grew its holdings in Arbutus Biopharma by 0.
7% during the 4th quarter. Vanguard Group Inc. now owns 8,980,864 shares of the biopharmaceutical company’s stock valued at $29,367,000 after buying an additional 62,282 shares in the last quarter.
Barclays PLC increased its stake in Arbutus Biopharma by 466.3% in the 3rd quarter. Barclays PLC now owns 272,029 shares of the biopharmaceutical company’s stock worth $1,047,000 after acquiring an additional 223,995 shares during the last quarter.
State Street Corp raised its holdings in shares of Arbutus Biopharma by 50.2% during the 3rd quarter. State Street Corp now owns 4,407,133 shares of the biopharmaceutical company’s stock worth $16,967,000 after acquiring an additional 1,472,652 shares in the last quarter.
Finally, Franklin Resources Inc. purchased a new position in shares of Arbutus Biopharma in the fourth quarter valued at $301,000. Institutional investors own 43.
79% of the company’s stock. Arbutus Biopharma Stock Down 0.6 %ABUS stock opened at $3.
19 on Wednesday. Arbutus Biopharma Co. has a twelve month low of $2.
63 and a twelve month high of $4.73. The stock has a market capitalization of $610.
82 million, a price-to-earnings ratio of -7.42 and a beta of 1.45.
The firm’s fifty day simple moving average is $3.28 and its two-hundred day simple moving average is $3.45.
Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.
08) by $0.01. The company had revenue of $1.
57 million for the quarter, compared to the consensus estimate of $2.20 million. Arbutus Biopharma had a negative net margin of 1,137.
65% and a negative return on equity of 68.18%. As a group, equities research analysts expect that Arbutus Biopharma Co.
will post -0.39 EPS for the current year. Analyst Upgrades and DowngradesABUS has been the topic of a number of recent research reports.
StockNews.com raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, March 29th. Chardan Capital restated a “buy” rating and set a $5.
00 target price on shares of Arbutus Biopharma in a research report on Friday, March 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research report on Tuesday, January 21st.
One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $5.50.
Get Our Latest Stock Analysis on Arbutus BiopharmaArbutus Biopharma Company Profile (Free Report)Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.Read MoreFive stocks we like better than Arbutus BiopharmaManufacturing Stocks InvestingHow to Invest in Micro-Cap Stocks Like a ProHow to Read Stock Charts for BeginnersInvestors Sell Microsoft Stock on OpenAI News—Time to Buy? 3 Must-Buy Warren Buffett Stocks for Volatile TimesTake-Two Interactive: A Defensive Play Set to Explode.
